Immunovant (IMVT) PT Raised to $45 at Chardan Capital Markets Following Data
Tweet Send to a Friend
Chardan Capital Markets analyst Gbola Amusa raised the price target on Immunovant (NASDAQ: IMVT) to $45.00 while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
